image01
.

News

Notice of the 44th Annual General Meeting and Proxy Form of The ACME Laboratories Ltd. Date: 10-12-2020

Notice of 44th Annual General Meeting

Form of Proxy-The 44th Annual General Meeting

ACME has launched THREE 1st time in Bangladesh products Date: 11-11-2020

The ACME Laboratories Ltd., a leading pharmaceutical company in Bangladesh is always focused on developing new products for our valued customers. Recently ACME has launched THREE new Products for the 1st Time in Bangladesh at a time. This is another step of ACME towards excellence. The new products are-

  1. Elago (Elagolix) Tab
    Uses: For endometriosis pain
  2. Halotaz (Halobetasol Propionate & Tazarotene) Lotion
    Uses: For plaque psoriasis
  3. Nystat Plus (Chlorhexidine Hydrochloride & Nystatin) Cream
    Uses: For fungal and/or bacterial infections including ringworm, athlete’s foot, nappy rash etc.

Till now ACME’s total 1st time in Bangladesh Brands for this year is FIVE which covers different therapeutic class like- Hormone, Skin, Respiratory and CNS.

The ACME Laboratories Ltd. declared 25% cash dividend Date: 15-10-2020

This is for information of all concerned that the Board of Directors of The ACME Laboratories Ltd. in its 119th Meeting held on Wednesday, the 14 October 2020 during 3.30 p.m. to 5.30 p.m. through Digital Platform has approved the Audited Financial Statements and declared 25% cash dividend for the year ended on 30 June 2020.

The Price Sensitive Information (PSI) is also available in the website of the Company at www.acmeglobal.com.

Launching of Zolpidem tablet in the US Market Date: 14-10-2020

This is for information of all concerned that the Board of Directors of The ACME Laboratories Ltd. in its 119th Meeting held on 14 October 2020 during 3.30 p.m. to 5.30 p.m. through Digital Platform noted with immense pleasure, the launching of Zolpidem (5 mg. and 10mg.) tablet in the US Market through contract manufacturing.

It may be noted that exploring in the US Market has been one of the ACME’s most ambitious and dream projects which will generate yearly earnings of US$ 50,000.00 approximately.

The Price Sensitive Information (PSI) is also available in the website of the Company at www.acmeglobal.com.

Fight Against Covid- 19 Date: 06-04-2020

ACME Joins with DGDA to fight against Coronavirus by donating high quality PPE for healthcare professionals.

Leading pharmaceutical manufacturing company, ACME, has donated high quality personal protective equipment (PPE) to protect the health care professionals, serving the Covid-19 patients in the amid situation of coronavirus pandemic. On Sunday, on behalf of the company’s Management, Md. Ferdous Khan, Director Sales & Distribution, General Manager of Procurement Division, Mr. Sayed Hossain Patwary and Deputy General Manager of Marketing Division, Mohammad Ziauddin, handed over the first consignment of PPE which includes protective gowns, face masks, hand gloves etc. to the Directorate General of Drug Administration, Major General Md. Mahbubur Rahman.

Achievement of Excellence Award of ISO Practice Date: 20-01-2020

The ACME Laboratories Ltd. has achieved the Excellence Award of ISO certification body, TQCSI as the best client of the year 2019 in Bangladesh. This recognition is based on the best demonstration of excellence in management system development, its implementation and maintenance throughout the organization which was assessed during the external audits time to time.

Management congratulates all of the employees working at The ACME Laboratories Ltd. and expresses their heart felt facilitations for the wonderful work done which has helped the company achieving this remarkable recognition.

Management believes, this award is the result of concerted effort from every individual of all levels and a comprehensive adherence to the compliance guidelines, written procedures & SOPs and also strong commitment towards excellence.

Commencement of Commercial Production of Steroid and Hormone facility Date: 30-06-2019

The Board of Directors in its 104th Meeting held on 30 June 2019 at 3.30 p.m. at the Corporate Office of the Company, Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka-1207 is pleased to declare the commencement of Commercial Production of its state-of-the-art Steroid and Hormone facility at Dhulivita, Dhamrai, Dhaka after successful completion of trail production.

It should be noted here that the last Annual General Meeting(AGM) of the Company, it was unanimously approved by the Shareholders that two projects out of three projects against which the fund was raised through Initial Public Offering (IPO) namely (1) Penicillin and (2) Steroid and Hormone projects will start commercial production within 30 June 2019. Accordingly, Penicillin project has already been started commercial production on 12 June 2019 for which necessary Price Sensitive Information (PSI) was published within the time limit. Now, the second project e.g. Steroid and Hormone project has been approved for commencement of commercial production.

Commencement of Commercial Production of Penicillin facility Date: 12-06-2019

The Board of Directors in its 103rd Meeting held on 12 June 2019 at 3.30 p.m. at the Corporate Office of the Company, Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka-1207 is pleased to declare the commencement of Commercial Production of its state-of-the-art Penicillin facility at Dhulivita, Dhamrai, Dhaka after successful completion of trail production.

It should be noted here that the aforesaid Penicillin facility is one of the three projects against which the fund was raised through Initial Public Offering (IPO).

Achieved Certificate of GMP Compliance from UK MHRA Date: 10-03-2019

The Board of Directors in its 99th Meeting held on 10 March 2019 at 3.00 p.m. at the Corporate Office of the Company, Court de la ACME, 1/4, Kallayanpur, Mirpur Road, Dhaka-1207 endorsed with immense pleasure the certificate of GMP Compliance from UK MHRA (Medicines and Healthcare Products Regulatory Agency of UK) following successful inspection of its Solid Dosage Unit (SDU) at Dhulivita, Dhamrai, Dhaka-1350, Bangladesh.

It may be noted that this success opens the doors for the company to enter UK and other European Markets.

Notification for General Information of the Shareholders Date: 22-11-2018

This is for the kind information of all our valued shareholders that the Annual Report 2017-2018 of The ACME Laboratories Ltd. in soft form, including all relevant Annual Audited Financial Statements, Management’s Discussion and Analysis, Report or Certificate on Compliance of the Corporate Governance Code and Director’s Report along with the notice of the 42nd Annual General Meeting have been transmitted to the respective shareholders of the Company through their E-mail ID available in their Beneficiary Owners (BO) accounts with the Depository.

The members whose E-mail ID were not updated with BO Accounts on the record date are requested to provide us the correct E-mail ID before 4 December 2018 as we can send the soft copy of the Annual Report 2017-2018 before AGM.

The members may also collect the Annual Report from the website of the ACME Laboratories Ltd. (www.acmeglobal.com) linked with the Stock Exchanges.

The members may also collect the Annual Report from the Investors Relation Department of the Company or from the AGM venue by submitting the written request within 4 December 2018.

This is in compliance with the Bangladesh Securities and Exchange Commission’s Notification No. BSEC/CMRRCD/2006-158/208/Admin/81; dated: 20 June 2018.

Comments are closed.